| Target Price | ¥2,371.50 |
| Price | ¥1,748.50 |
| Potential |
35.63%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Santen Pharmaceutical 2027 .
The average Santen Pharmaceutical target price is ¥2,371.50.
This is
35.63%
register free of charge
¥2,940.00
68.14%
register free of charge
¥1,919.00
9.75%
register free of charge
|
|
| A rating was issued by 13 analysts: 9 Analysts recommend Santen Pharmaceutical to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Santen Pharmaceutical stock has an average upside potential 2027 of
35.63%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 291.62 | 307.12 |
| 2.79% | 5.31% | |
| EBITDA Margin | 20.58% | 22.61% |
| 0.38% | 9.84% | |
| Net Margin | 12.81% | 13.01% |
| 6.06% | 1.53% |
10 Analysts have issued a sales forecast Santen Pharmaceutical 2027 . The average Santen Pharmaceutical sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Santen Pharmaceutical EBITDA forecast 2027. The average Santen Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Santen Pharmaceutical Analysts have issued a net profit forecast 2027. The average Santen Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 114.06 | 124.41 |
| 10.04% | 9.07% | |
| P/E | 14.05 | |
| EV/Sales | 1.75 |
10 Analysts have issued a Santen Pharmaceutical forecast for earnings per share. The average Santen Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Santen Pharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


